2026 IPO bonanza! Over 90% of new stocks rose on their debut!
At a Glance: May's Hot IPOs - IMPACT Therapeutics and UISEE Technologies Passed! Tianxing Medical and Cofoe Medical Are About to Go Public
Hello fellow investors! Your dedicated Futu IPO correspondent is here with the scoop on May’s and 2026’s hot HK IPOs. Fellow investors, check it out now!
![Hello fellow investors! Your dedicated Futu IPO correspondent is here with the scoop on May’s and 2026’s hot HK IPOs. Fellow investors, check it out now![Cheerlead][Cheerlead] Jet Tech:$METIS TECHBIO-P (07666.HK)$A leader in artificial intelligence nanomaterials innovation, committed to the delivery and application of payloads across all forms of life. NanoForge is the cornerstone of the company’s proprietary, synergistically integrated AI-driven nanotechnology innovation system, encompassing a vast lipid library generated from scratch, AI foundational models, METiS AI agents, quantum chemistry and molecular dynamics simulations, and an AI-powered high-throughput screening platform. Tianxing Medical:$STAR SPORTS MED (01609.HK)$A China-based medical device company focused on clinical solutions in sports medicine. According to CIC Consulting data, based on 2024 sales revenue, the company ranks as the fourth-largest provider of sports medicine equipment in China, holding approximately 6.5% of the Chinese sports medicine implants and devices market, and is also the largest domestic provider of sports medicine equipment. Cofoe Healthcare:$COFOE MEDICAL (01187.HK)$One of the largest home medical device enterprises in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. $UISEE TECH (01511.HK)$: According to HKEX on April 19th...](https://nnqimage.futunn.com/sns_client_feed/12147652/20260430/web-1777506188226-BtSdAkSbMb.png/big?area=999&is_public=true&imageMogr2/ignore-error/1/format/webp)
Jet Tech:$METIS TECHBIO-P (07666.HK)$A leader in artificial intelligence nanomaterials innovation, committed to the delivery and application of payloads across all forms of life. NanoForge is the cornerstone of the company’s proprietary, synergistically integrated AI-driven nanotechnology innovation system, encompassing a vast lipid library generated from scratch, AI foundational models, METiS AI agents, quantum chemistry and molecular dynamics simulations, and an AI-powered high-throughput screening platform.
Tianxing Medical:$STAR SPORTS MED (01609.HK)$It is a China-based medical device company focusing on clinical solutions for sports medicine. According to data from灼识谘询, the company ranked as the fourth-largest provider of sports medicine equipment in China by sales revenue in 2024, with a market share accounting for approximately 6.5% of China's sports medicine implants and devices market. It is also the largest domestic provider of sports medicine equipment in China.
Kefu Medical:$COFOE MEDICAL (01187.HK)$The company is one of the largest home-use medical device enterprises in China. According to弗若斯特沙利文, based on domestic revenue in 2024, the company ranked second among all home-use medical device enterprises in China, with a market share of 2.1%.
$UISEE TECH (01511.HK)$According to the disclosure by the Hong Kong Stock Exchange on April 19, the company passed the listing hearing.中信证券is the sole sponsor. The prospectus shows that the company is a technology-driven leader in the Greater China region, specializing in unmanned L4-level autonomous driving technology. The company currently focuses on commercial vehicles in closed scenarios (especially in airports and industrial zones). Its solutions are applicable across all scenarios and have been applied in various open and closed environments, covering logistics, operational, and motor vehicles, spanning from L2 to L4 autonomous driving levels.
$IMPACT THERAP-B (07630.HK)$According to the disclosure by the Hong Kong Stock Exchange on April 20, the company passed the listing hearing. Goldman Sachs and CICC are the joint sponsors. The prospectus shows that the company is a biotechnology firm at the commercialization stage, dedicated to advancing precision cancer therapies based on the synthetic lethality mechanism globally. It aims to develop treatments to meet unmet medical needs of cancer patients. The company’s core product,塞纳帕利, has been approved for marketing in China as a first-line maintenance therapy for ovarian cancer, applicable to the entire population (regardless of mutation status), demonstrating compelling clinical characteristics.
Which upcoming IPO are fellow investors most looking forward to? Are there other companies that you hope will successfully list on the Hong Kong Exchange? Come vote and interact in the comment section!>>
>>Further reading:
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
![Hello fellow investors! Your dedicated Futu IPO correspondent is here with the scoop on May’s and 2026’s hot HK IPOs. Fellow investors, check it out now![Cheerlead][Cheerlead] Jet Tech:$METIS TECHBIO-P (07666.HK)$A leader in artificial intelligence nanomaterials innovation, committed to the delivery and application of payloads across all forms of life. NanoForge is the cornerstone of the company’s proprietary, synergistically integrated AI-driven nanotechnology innovation system, encompassing a vast lipid library generated from scratch, AI foundational models, METiS AI agents, quantum chemistry and molecular dynamics simulations, and an AI-powered high-throughput screening platform. Tianxing Medical:$STAR SPORTS MED (01609.HK)$A China-based medical device company focused on clinical solutions in sports medicine. According to CIC Consulting data, based on 2024 sales revenue, the company ranks as the fourth-largest provider of sports medicine equipment in China, holding approximately 6.5% of the Chinese sports medicine implants and devices market, and is also the largest domestic provider of sports medicine equipment. Cofoe Healthcare:$COFOE MEDICAL (01187.HK)$One of the largest home medical device enterprises in China. According to Frost & Sullivan, based on domestic revenue in 2024, the company ranks second among all home medical device companies in China, with a market share of 2.1%. $UISEE TECH (01511.HK)$: According to HKEX on April 19th...](https://nnqimage.futunn.com/sns_client_feed/12147652/20260430/web-1777506280855-kkBWWv7nuX.png/big?area=999&is_public=true&imageMogr2/ignore-error/1/format/webp)
Editor/Vincent
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Comments (5)
to post a comment
14
34